← All Posts
RIG
Rigel Pharmaceuticals, Inc.
May 15, 2026
•
Author: Phil Ratcliff
| Item |
Proposal |
Vote |
| 1a |
Alison Hannah, M.D. |
✓ For(225.342)
|
| 1b |
Walter Moos, Ph.D. |
✓ For(225.342)
|
| 1c |
Raul Rodriguez |
Withhold(225.342)
|
| 2 |
To approve an amendment to our 2018 Equity Incentive Plan, as amended (the "Amended 2018 Plan"), to add an additional 500,000 shares to the number of shares of common stock authorized for issuance under the Amended 2018 Plan. |
✓ For(225.342)
|
| 3 |
To approve an amendment to our 2000 Employee Stock Purchase Plan, as amended (the "Amended 2000 ESPP"), to, among other things, add an additional 360,000 shares to the number of shares of common stock authorized for issuance under the Amended 2000 ESPP. |
✓ For(225.342)
|
| 4 |
To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the accompanying proxy statement. |
✓ For(225.342)
|
| 5 |
To ratify the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026. |
✓ For(225.342)
|
This article was written for information purposes only and its content should not be
construed by any consumer and/or prospective client as rebel Financial's solicitation
to affect, or attempt to affect transactions in securities, or the rendering of
personalized investment advice for compensation. No client or prospective client should
assume that any such discussion serves as the receipt of, or a substitute for,
personalized advice from rebel Financial, or from any other investment professional.
See our disclosures page for more information.
rebel Financial